Associated Press Cannot Explain Bewildering Reporting on FDA’s Tracy Hoeg and Antidepressant Risks

Key Takeaways

• AP story mischaracterizes FDA conflict‑of‑interest rules.
• No legal definition of “friend” in FDA COI policy.
• Nature study links SSRIs to fetal brain changes.
• Urato’s petition follows successful 2019 Makena withdrawal.
• Misreporting could sway public perception of drug safety.

Summary

The Associated Press published a story alleging that FDA senior regulator Dr. Tracy Hoeg was pushing a petition from Dr. Adam Urato to add pregnancy‑risk warnings to antidepressants and that their personal relationship constituted a conflict of interest. The author, a former Senate staffer and conflict‑of‑interest expert, argues the AP piece contains factual errors, noting that neither the FDA nor HHS define a “friend” as a conflict under any regulation. He cites a recent Nature Communications study confirming fetal risks from SSRIs and points to Urato’s earlier successful petition that led to the withdrawal of the drug Makena. The post highlights the lack of response from AP and the FDA, framing the article as a mis‑informed hit piece.

Pulse Analysis

Media outlets wield significant influence when they cover regulatory bodies like the FDA, and errors can quickly erode public confidence. The AP article in question conflates a professional interaction between Dr. Tracy Hoeg and Dr. Adam Urato with a prohibited conflict of interest, despite the agency’s clear guidelines that require disclosure of financial ties, not personal acquaintances. By failing to verify whether the term “friend” appears in any official policy, the report exemplifies a broader trend of sensationalism that undermines rigorous journalism in health reporting.

Scientific evidence on antidepressant use during pregnancy has evolved, with a May 2025 Nature Communications paper documenting altered brain activity and increased anxiety in children exposed in utero. These findings reinforce long‑standing concerns among obstetricians and psychiatrists and provide a factual basis for petitions urging the FDA to update labeling. Dr. Urato’s current petition builds on his 2019 collaboration with Public Citizen that successfully removed the premature‑birth drug Makena, demonstrating how well‑documented research can translate into regulatory change when presented through formal channels.

The fallout from inaccurate coverage extends beyond a single story; it shapes stakeholder perceptions, influences legislative oversight, and can affect patient decision‑making. Health journalists must prioritize primary sources, such as FDA policy documents and peer‑reviewed studies, to avoid propagating unfounded claims. For regulators, transparent communication about conflict‑of‑interest standards and the scientific rationale behind labeling decisions can preempt misinformation and reinforce the credibility of the agency’s protective role.